NEW YORK (January 31, 2023)—The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world’s deadliest neglected diseases remained woefully inadequate and largely stagnant. Specifically, global investments in tuberculosis (TB) research and development (R&D) totaled $723 million in 2021, comparable to last year’s total and far short of the $2.16 billion estimated by Stop TB Partnership as needed annually to develop and deliver the suite of drug regimens, vaccines, and diagnostics that can end the TB pandemic. TB is regaining its dubious distinction as the world’s deadliest infectious disease, with more than 10 million people afflicted and 1.6 million dying each year.  

TB Alliance will convene a special Stakeholders Association meeting as a virtual event on 23 June 2022.

On 11 April 2022, FIND, the global alliance for diagnostics, TB Alliance and the International AIDS Vaccine Initiative (IAVI) will host a webinar bringing together a panel of experts to review both new and experimental tools that have the potential to end TB for good, and what is needed to bring them to scale and achieve public health impact.

Statement on 2021 G-FINDER Report

NEW YORK, NY (20 January 2022) — Today, TB Alliance announced that it has received funding from the United States Agency for International Development (USAID) to jumpstart the search for new tuberculosis (TB) treatments, optimize current treatments so that they can treat children as well as adults, and strengthen health systems in high-TB-burden countries so that all people with TB disease can get treated and quickly return to full health. The funding of up to US$30 million will be administered over a period of 5 years.

Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug.

On 12 August 2021, TB Alliance hosted a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.

TB Alliance and KNCV Tuberculosis Foundation published a study in BMC Public Health, focused on collecting stakeholder views (in Nigeria, Indonesia, and Kyrgyzstan) regarding the acceptability, feasibility, and likelihood of stakeholders implementing the BPaL regimen. BPal is a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.